About AT&TWe help more than 100 million U.S. families, friends and neighbors, plus nearly 2.5 million businesses, connect to greater possibility. From the first phone call 140+ years ago to our 5G wireless and multi- gig internet offerings today, we @ATT innovate to improve lives. For more information about AT&T Inc. (NYSE:T), please visit us at about.att.com. Investors can learn more at investors.att.com. © 2025 AT&T Intellectual Property. All rights reserved. AT&T and the Globe logo are registered tradem ...

交易暂停事件核心 - 美国证券交易委员会（SEC）因怀疑公司证券存在潜在操纵行为，旨在人为抬高股价和交易量，于2025年11月14日下达了交易暂停令 [1][2] - 该交易暂停令于2025年12月1日东部标准时间晚上11:59到期 [1] - 交易暂停不涉及关于公司市场信息准确性和充分性的问题，公司亦无信息表明交易涉及现任高管、董事或员工所持股份，或由现任管理层所知人士进行 [2] 公司应对措施 - 公司承诺并正全力配合SEC对其证券交易的调查，同时也全力配合其他资本市场监管机构的相关问询，包括回应纳斯达克监管局要求提供额外信息的请求 [3] - 公司完全支持其已发布的所有新闻稿及公开文件（包括已公布的财务报表）的准确性和内容 [3] - 公司聘请了政府调查和证券执法业务主席Jacob Frenkel提供咨询，其以辩护和诉讼交易暂停案件闻名，并曾成功诉讼使SEC撤销了对某发行人证券的交易暂停 [5] 公司立场与沟通 - 公司未曾、也不会与互联网通讯或聊天板的发布者沟通，且未曾、也不支付任何人以推广其证券 [4] - 公司保留投资者关系公司仅是为了确保按监管要求及时传播重大及财务信息，并建立对需披露的公司动态的公众认知 [4] - 公司董事长兼首席执行官表示不支持其证券的不当交易活动，并将支持所有法律努力，积极追查任何试图损害公司股东或人为影响公司证券价值的人士 [6] 公司业务背景 - 公司是一家专注于先进技术与创新的定制消费品制造商，于2007年成立，总部位于上海，并于2025年7月成功完成纳斯达克首次公开募股 [1][6][7] - 公司在中国的浙江和河南省设有生产设施，整合数字生产、软件开发、产品设计、品牌管理、在线销售和国际贸易，提供小批量纺织品定制服务 [7] - 产品包括背包、购物袋、围裙及其他促销物品，并使用可持续材料及专有订单管理技术，提供高质量、高性价比产品，同时强调环境保护和社会责任 [7][8]

Geiger to Begin Hook Drill Program Targeting Radioactive Alteration Systems in FebruaryDecember 01, 2025 6:00 AM EST | Source: Geiger Energy CorporationKey HighlightsHook Project in Athabasca is planning a February 2026 drill program to the TT and TAB areas, which exhibit strong alteration and elevated radioactivity.TT and TAB areas exhibit thick alteration zones with elevated radioactivity and pathfinder geochemistry, consistent with major Athabasca Basin uranium deposit corridors.TT target: ...

Dec 1, 2025 6:00 AM Eastern Standard Time American Strategic Investment Co. Announces NYSE Acceptance of Continued Listing Compliance Plan Share NEW YORK--(BUSINESS WIRE)--American Strategic Investment Co. (NYSE: NYC) ("ASIC†or the "Company†) announced today that the New York Stock Exchange ("NYSE†) has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Section 802.01B of the NYSE Listed Company Manual. "We are pleased that the NYSE has accepted o ...

WASHINGTON, D.C. / ACCESS Newswire / December 1, 2025 / National Energy Services Reunited Corp. ("NESR" or the "Company") (Nasdaq:NESR) an international, industry-leading provider of integrated energy services in the Middle East and North Africa ("MENA") region, announced the celebratory signing of its recently-announced unconventional frac contract, as part of the Saudi-US Investment Forum 2025 and His Royal Highness' delegation visit to President Trump, in Washington D.C. ...

Accessibility StatementSkip Navigation All dollar amounts are in Canadian dollars ("$") unless otherwise indicated. Figure 2: Milled Reserve Schedule (CNW Group/Thesis Gold Inc.) Figure 3: Longitudinal Projection of Lawyers Underground Looking West (CNW Group/Thesis Gold Inc.) VANCOUVER, BC, Dec. 1, 2025 /PRNewswire/ - Thesis Gold Inc. ("Thesis" or the "Company") (TSXV: TAU) (WKN: A3EP87) (OTCQX: THSGF) is pleased to announce positive results from an independent Prefeasibility Study ("PFS") for its 100% own ...

Toronto, Ontario--(Newsfile Corp. - December 1, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands is pleased to announce the grand opening of their newest Heal Wellness ("Heal") location in the Bridgeland neighbourhood of Calgary, Alberta. Located at 602 1st Ave NE, this new location is operated by one of our multi-unit franchisee partners and marks Heal's 6th location in the City of Calgary, 9th opened lo ...

融资情况 - 公司通过母公司Juniper Radiopharma LLC完成超额认购且规模扩大的种子轮融资，金额为4000万美元 [1] - 本轮融资由NovaCapital、多位高净值人士及Club Degli Investitori成员共同领投 [1] 公司定位与团队 - 公司是一家创新的放射性药物研发公司，专注于开发用于成像和治疗的放射性药物 [2] - 公司由Alex Agnoletto（首席执行官）、Indranil Nandi博士（首席运营官）和Kyle Hoffmann博士（生产总监）领导 [2] - 管理团队在全球放射性药物的开发和生产领域拥有深厚专业知识 [2] 产品管线与前景 - 公司产品管线目前处于保密状态，包含多个处于不同开发阶段的资产 [2] - 公司管线以患者为中心，被认为在未来几年对放射性药物成像和治疗领域具有变革性潜力 [3]

核心进展 - 公司宣布其潜在首创双特异性B7H3/PTK7 TOP1抗体偶联药物IDE034的研究性新药申请已获得美国FDA批准，将启动一期临床试验[1] - 公司预计于2026年第一季度开始患者入组，初步评估已知表达B7H3和PTK7的实体瘤患者，包括肺癌、结直肠癌、头颈癌和卵巢/妇科癌症[1] 临床开发计划 - 一期临床试验将评估IDE034在B7H3和PTK7共表达的实体瘤患者中的效果[1] - 根据人类蛋白质图谱数据库，B7H3/PTK7在肺癌、结直肠癌和头颈癌中的共表达率分别约为30%、46%和27%[1] 药物作用机制与临床前数据 - IDE034在临床前研究中显示出强大的抗肿瘤活性，并在B7H3/PTK7阳性肿瘤模型中观察到深度且持久的肿瘤消退[3] - TOP1抑制诱导复制应激和DNA损伤，可能增加对PARG通路的依赖性，因此IDE034与公司PARG抑制剂IDE161的联合方法可能增强抗肿瘤活性[3] - 临床前研究显示IDE034与IDE161 PARG抑制剂联合使用可增强疗效，公司目标在2026年上半年的一次主要医学会议上分享支持该联合疗法原理的额外临床前数据[2] 公司战略与产品管线 - 公司目前拥有三个潜在首创的临床阶段项目，专注于通过PARG DNA损伤修复组合机制增强TOP1 ADC的疗效[2] - 公司致力于发现和开发针对癌症的转化疗法，构建了专注于合成致死和抗体偶联药物的深度产品管线，用于分子定义的实体瘤适应症[4] - 公司的方法整合了小分子药物发现、结构生物学和生物信息学的专业知识，旨在开发与疾病遗传驱动因素一致的、量身定制的潜在首创靶向疗法[4]

Dec 1, 2025 6:00 AM Eastern Standard Time "Marq represents an exciting next chapter for the Ares Real Estate business, building on our top three global leadership position in one of our highest conviction sectors,†said Julie Solomon, Co-Head of Ares Real Estate. "At its core, Marq aims to deliver global scale and local operational excellence to our logistics tenants through a commitment to a simple but powerful mission—to be a strategic partner in their success.†Ares Real Estate is one of the world's most ...